The University of Chicago Header Logo

Connection

Mark Kozloff to Adult

Back to Details
This is a "connection" page, showing publications Mark Kozloff has written about Adult.
Mark Kozloff
Connection Strength
0.350
Adult
  1. Real-world clinical experience in the Connect® chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. Br J Haematol. 2016 Dec; 175(5):892-903.
    View in: PubMed
    Score: 0.036
  2. A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2013 Dec; 12(4):248-54.
    View in: PubMed
    Score: 0.029
  3. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. Br J Cancer. 2012 Oct 09; 107(8):1277-85.
    View in: PubMed
    Score: 0.027
  4. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology. 2010; 78(5-6):329-39.
    View in: PubMed
    Score: 0.023
  5. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol. 2010 Jul; 21(7):1436-1441.
    View in: PubMed
    Score: 0.022
  6. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009 Sep; 14(9):862-70.
    View in: PubMed
    Score: 0.022
  7. Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing. Clin Cancer Res. 2020 01 01; 26(1):18-24.
    View in: PubMed
    Score: 0.011
  8. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer. 2019 05 15; 125(10):1629-1636.
    View in: PubMed
    Score: 0.010
  9. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Br J Cancer. 2018 11; 119(10):1208-1214.
    View in: PubMed
    Score: 0.010
  10. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Ann Oncol. 2018 09 01; 29(9):1932-1938.
    View in: PubMed
    Score: 0.010
  11. A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. Oncologist. 2017 03; 22(3):264-271.
    View in: PubMed
    Score: 0.009
  12. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Dec 20; 33(36):4284-92.
    View in: PubMed
    Score: 0.008
  13. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiol Drug Saf. 2014 Jul; 23(7):726-34.
    View in: PubMed
    Score: 0.008
  14. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study. Clin Oncol (R Coll Radiol). 2014 Jun; 26(6):323-32.
    View in: PubMed
    Score: 0.008
  15. Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. BMC Cancer. 2014 Mar 07; 14:166.
    View in: PubMed
    Score: 0.007
  16. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan 04; 14:5.
    View in: PubMed
    Score: 0.007
  17. Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia. Support Care Cancer. 2013 Oct; 21(10):2853-60.
    View in: PubMed
    Score: 0.007
  18. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist. 2012; 17(12):1486-95.
    View in: PubMed
    Score: 0.007
  19. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. Br J Cancer. 2012 Oct 09; 107(8):1268-76.
    View in: PubMed
    Score: 0.007
  20. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study. Eur J Cancer. 2012 May; 48(8):1126-32.
    View in: PubMed
    Score: 0.007
  21. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer. 2012 Mar; 13(2):123-8.
    View in: PubMed
    Score: 0.006
  22. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol. 2010 Dec; 21(12):2370-2376.
    View in: PubMed
    Score: 0.006
  23. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2010 Oct; 28(5):677-83.
    View in: PubMed
    Score: 0.005
  24. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar; 10(3):247-57.
    View in: PubMed
    Score: 0.005
  25. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
    View in: PubMed
    Score: 0.005
  26. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2008 Jun; 3(6):631-6.
    View in: PubMed
    Score: 0.005
  27. Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. J Thorac Oncol. 2006 Mar; 1(3):245-51.
    View in: PubMed
    Score: 0.004
  28. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005 Nov 01; 23(31):8033-40.
    View in: PubMed
    Score: 0.004
  29. Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP). Int J Radiat Oncol Biol Phys. 2004 Sep 01; 60(1):302-9.
    View in: PubMed
    Score: 0.004
  30. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. Clin Cancer Res. 2004 Aug 01; 10(15):4922-32.
    View in: PubMed
    Score: 0.004
  31. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol. 2004 Mar 15; 22(6):1110-7.
    View in: PubMed
    Score: 0.004
  32. Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J Clin Oncol. 1998 Aug; 16(8):2715-21.
    View in: PubMed
    Score: 0.003
  33. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol. 1996 May; 14(5):1663-71.
    View in: PubMed
    Score: 0.002
  34. Improved staging of B-cell non-Hodgkin's lymphoma patients with 99mTc-labeled LL2 monoclonal antibody fragment. Cancer Res. 1995 Dec 01; 55(23 Suppl):5764s-5770s.
    View in: PubMed
    Score: 0.002
  35. Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease. J Clin Oncol. 1995 Apr; 13(4):876-83.
    View in: PubMed
    Score: 0.002
  36. Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1993 Feb; 11(2):360-8.
    View in: PubMed
    Score: 0.002
  37. Zinc abuse and sideroblastic anemia. Am J Hematol. 1993 Feb; 42(2):227-8.
    View in: PubMed
    Score: 0.002
  38. Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach. Ann Oncol. 1992 Jan; 3(1):79-81.
    View in: PubMed
    Score: 0.002
  39. A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer. Cancer. 1990 Jul 15; 66(2):206-13.
    View in: PubMed
    Score: 0.001
  40. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1990 Feb; 8(2):241-7.
    View in: PubMed
    Score: 0.001
  41. Platinol (CDDP) and continuous intravenous infusion 5-fluorouracil in refractory stage IV breast cancer: a phase II study. Cancer Invest. 1990; 8(3-4):335-8.
    View in: PubMed
    Score: 0.001
  42. Response to secondary therapy in patients with adenocarcinoma of the breast previously treated with adjuvant chemotherapy. Cancer. 1983 Feb 01; 51(3):381-4.
    View in: PubMed
    Score: 0.001
  43. Multimodality therapy of stage III adenocarcinoma of the breast. J Surg Oncol. 1983 Jan; 22(1):5-8.
    View in: PubMed
    Score: 0.001
  44. Intracavitary bleomycin for the control of malignant effusions. J Surg Oncol. 1981; 16(3):273-7.
    View in: PubMed
    Score: 0.001
  45. Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-fluorouracil, adriamycin, and mitomycin C (FAM). Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):2049-51.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.